Rivastigmine transdermal patch: A review of its use in the management of dementia of the Alzheimers type

Drugs

Volumn 71, Issue 9, 2011, Pages 1209-1231

  Dhillon, Sohita ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Evaluations; Alzheimer's disease; Dementia; Rivastigmine general; Transdermal

Indexed keywords

DIAZEPAM; DIGOXIN; DONEPEZIL; DRUG METABOLITE; FLUOXETINE; GALANTAMINE; MEMANTINE; NAP 226 90; PLACEBO; RIVASTACH; RIVASTIGMINE; UNCLASSIFIED DRUG; WARFARIN;

ALZHEIMER DISEASE; ANEMIA; APPLICATION SITE ERYTHEMA; APPLICATION SITE PRURITUS; APPLICATION SITE REACTION; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BLISTER; BODY WEIGHT; CONFUSION; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FATIGUE; GASTRITIS; HEADACHE; HUMAN; HYPERTENSION; MAINTENANCE DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MUSCLE CRAMP; NAUSEA; OUTCOME ASSESSMENT; PLASMA PROTEIN BINDING; PNEUMONIA; POST HOC ANALYSIS; PULSE RATE; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECOMMENDED DRUG DOSE; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; SKIN ALLERGY; SOMNOLENCE; SYSTOLIC BLOOD PRESSURE; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSDERMAL PATCH; TREATMENT INDICATION; URINE INCONTINENCE; VOMITING;

ADMINISTRATION, CUTANEOUS; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; HUMANS; MEDICATION ADHERENCE; PHENYLCARBAMATES; TRANSDERMAL PATCH;

EID: 79959687706     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11206380-000000000-00000     Document Type: Article

References (69)

1. Greig NH, Utsuki T, Yu QS, et al. A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase. Curr Med Res Opin 2001; 17 (3): 159-65. (Pubitemid 34003119)
2. Grossberg GT. Cholinesterase inhibitors for the treatment of Alzheimer's disease: getting on and staying on. Current Therapeutic Research 2003 Apr; 64 (4): 216-35. (Pubitemid 36692841)
3. National Institute on Aging. Alzheimer's disease: fact sheet [online]. Available fromURL: http://www.nia.nih.gov/NR/rdonlyres/7DCA00DB-1362-4755-9E87- 96DF669EAE20/13991/ADFactSheetFINAL2510.pdf [Accessed 2010 Sep 21].
4. Alzheimer's Disease International. World Alzheimer report 2009 [online]. Available from URL: http://www.alz.org/national/documents/report-full- 2009worldalzheimerreport.pdf [Accessed 2010 Sep 21].
5. Alzheimer's Association. 2010 Alzheimer's Disease facts and figures [online]. Available from URL: http://www.alz.org/documents-custom/report- alzfactsfigures2010.pdf [Accessed 2010 Sep 21].
6. Alzheimer Europe. Estimated number of people (2006) with dementia [online]. Available from URL: http://ec.europa. eu/health/ph-information/ dissemination/diseases/alzheimer- en.htm [Accessed 2010 Sep 21].
7. Mayeux R. Early Alzheimer's disease. N Engl J Med 2010; 362 (23): 2194-201.
8. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med 2010 Jan 28; 362 (4): 329-44.
9. Qaseem A, Snow V, Cross JTJ, et al. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians.Ann InternMed 2008Mar 4; 148 (5): 370-8. (Pubitemid 351665468)
10. Rabins PV, Blacker D, Rovner BW, et al., on behalf of the APA Work Group on Alzheimer's Disease and other Dementias. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. 2nd ed. Am J Psychiatry 2007 Dec; 164 (12 Suppl.): 5-56.
11. Hort J, O'Brien JT, Gainotti G, et al. EFNS guidelines for the diagnosis and management of Alzheimer's disease. Eur J Neurol 2010 Oct; 17 (10): 1236-48.
12. Lyketsos CG, Colenda CC, Beck C, et al. Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease. Am J Geriatr Psychiatry 2006 Jul; 14 (7): 561-73.
13. National Institute for Health and Clinical Excellence. Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease: review of NICE technology appraisal guidance 111 [online]. Available from URL: http://guidance.nice.org.uk/TA217/Guidance/pdf/English [Accessed 2011 Apr 29].
14. Guay DR. Rivastigmine transdermal patch: role in the management of Alzheimer's disease. Consult Pharm 2008 Aug; 23 (8): 598-609.
15. Oertel W, Ross JS, Eggert K, et al. Rationale for transdermal drug administration in Alzheimer disease. Neurology 2007 Jul 24; 69 (4 Suppl. 1): S4-9. (Pubitemid 47205653)
16. Grossberg GT, Sadowsky C, Olin JT. Rivastigmine transdermal system for the treatment of mild to moderate Alzheimer's disease. Int J Clin Pract 2010; 64 (5): 651-60.
17. Darreh-Shori T, Jelic V. Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia. Expert Opin Drug Saf 2010 Jan; 9 (1): 167-76.
18. Jann MW. Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease. Pharmacotherapy 2000 Jan; 20 (1): 1-12. (Pubitemid 30036098)
19. Weinstock M. Selectivity of cholinesterase inhibition: clinical implications for the treatment of Alzheimer's disease. CNS Drugs 1999; 12 (4): 307-23. (Pubitemid 29503416)
20. Lefèvre G, Sedek G, Jhee SS, et al. Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients. Clin Pharmacol Ther 2008 Jan; 83 (1): 106-14.
21. Grossberg GT, Stahelin HB, Messina JC, et al. Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications. Int J Geriatr Psychiatry 2000 Mar; 15 (3): 242-7. (Pubitemid 30179175)
22. Muhlack S, Przuntek H, Mü ller T. Transdermal rivastigmine treatment does not worsen impaired performance of complex motions in patients with Alzheimer's disease. Pharmacopsychiatry 2006 Jan; 39 (1): 16-9. (Pubitemid 43235445)
23. Lefèvre G, Bü che M, Sedek G, et al. Similar rivastigmine pharmacokinetics and pharmacodynamics in Japanese and white healthy participants following the application of novel rivastigmine patch. J Clin Pharmacol 2009; 49 (4): 430-43.
24. Eskander MF, Nagykery NG, Leung EY, et al. Rivastigmine is a potent inhibitor of acetyl- and butyrylcholinesterase in Alzheimer's plaques and tangles. Brain Res 2005 Oct 26; 1060 (1-2): 144-52. (Pubitemid 41483599)
25. Rakonczay Z. Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain. Acta Biol Hung 2003; 54 (2): 183-9. (Pubitemid 37105630)
26. Darvesh S, Walsh R, Kumar R, et al. Inhibition of human cholinesterases by drugs used to treat Alzheimer disease. Alzheimer Dis Assoc Disord 2003; 17 (2): 117-26. (Pubitemid 36736847)
27. Lee N-Y, Kang Y-S. The inhibitory effect of rivastigmine and galantamine on choline transport in brain capillary endothelial cells. Biomol Ther 2010; 18 (1): 65-70.
28. Novartis Pharmaceuticals Corporation. Exelon- patch (rivastigmine transdermal system): US prescribing information [online]. Available from URL: http://www.pharma. us.novartis.com/product/pi/pdf/exelonpatch.pdf [Accessed 2010 Nov 24].
29. European Medicines Agency. Exelon- (rivastigmine): summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/docs/en- GB/document- library/EPAR-Product-Information/human/000169/WC 500032598.pdf [Accessed 2010 Nov 24].
30. Muller T. Rivastigmine in the treatment of patients with Alzheimer's disease. Neuropsychiatr Dis Treat 2007; 3 (2): 211-8. (Pubitemid 46864060)
31. Lefèvre G, Sedek G, Huang HLA, et al. Pharmacokinetics of a rivastigmine transdermal patch formulation in healthy volunteers: relative effects of body site application. J Clin Pharmacol 2007 Apr; 47 (4): 471-8. (Pubitemid 46465956)
32. Lefèvre G, Pommier F, Sedek G, et al. Pharmacokinetics and bioavailability of the novel rivastigmine transdermal patch versus rivastigmine oral solution in healthy elderly subjects. J Clin Pharmacol 2008; 48 (2): 246-52.
33. Mercier F, Lefèvre G, Huang HLA, et al. Rivastigmine exposure provided by a transdermal patch versus capsules. Curr Med Res Opin 2007 Dec; 23 (12): 3199-204.
34. Winblad B, Cummings J, Andreasen N, et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease-rivastigmine patch versus capsule. Int J Geriatr Psychiatry 2007 May; 22 (5): 456-67. (Pubitemid 46831690)
35. Winblad B, Grossberg G, Frö lich L, et al. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology 2007 Jul 24; 69 (4 Suppl. 1): S14-22. (Pubitemid 47205655)
36. Winblad B, Kawata AK, Beusterien KM, et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. Int J Geriatr Psychiatry 2007 May; 22 (5): 485-91. (Pubitemid 46831693)
37. Blesa R, Ballard C, Orgogozo JM, et al. Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease. Neurology 2007 Jul 24; 69 (4 Suppl. 1): S23-8. (Pubitemid 47205656)
38. Cummings JL, Ferris SH, Farlow MR, et al. Effects of rivastigmine transdermal patch and capsule on aspects of clinical global impression of change in Alzheimer's disease: a retrospective analysis. Dementia Geriatr Cogn Disord 2010; 29 (5): 406-12.
39. Grossberg GT, Schmitt FA, Meng X, et al. Reviews: Effects of transdermal rivastigmine on ADAS-cog items in mildto- moderate Alzheimer's disease. Am J Alzheimers Dis Other Demen 2010 Dec; 25 (8): 627-33.
40. Grossberg G, Meng X, Olin JT. Impact of rivastigmine patch and capsules on activities of daily living in Alzheimer's disease. Am J Alzheimers Dis Other Demen 2011 Feb; 26 (1): 65-71.
41. Alva G, Grossberg GT, Schmitt FA, et al. Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses. Int J Geriatr Psychiatry 2011 Apr; 26 (4): 356-63.
42. Schmidt R. A naturalistic study of rivastigmine transdermal patch in outpatient services in Austria [abstract no. P2- 245]. 2009 International Conference on Alzheimer's Disease; 2009 Jul 11-16; Vienna.
43. Sadowsky CH, Dengiz A, Olin JT, et al. Switching from donepezil tablets to rivastigmine transdermal patch in Alzheimer's disease. Am J Alzheimers Dis Other Demen 2009 Jun 31; 24 (3): 267-75.
44. Sadowsky CH, Dengiz A, Meng X, et al. Switching from oral donepezil to rivastigmine transdermal patch in Alzheimer's disease: 20-week extension phase results. Primary Care Companion J Clin Psychiatry 2010; 12 (5): e1-8.
45. Farlow MR, Alva G, Meng X, et al. A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis. CurrMed Res Opin 2010 Feb; 26 (2): 263-9.
46. Grossberg G, Sadowsky C, Fö rstl H, et al. Safety and tolerability of the rivastigmine patch: results of a 28-week open-label extension. Alzheimer Dis Assoc Disord 2009 Apr-Jun; 23 (2): 158-64.
47. Shua-Haim JR, Yap C, Kretov A, et al. Results of next-day crossover study of rivastigmine oral capsules (Exelon) to rivastigmine patch (Exelon Patch) in Alzheimer's disease patients: a two-month clinical experience [abstract no. P2- 411]. 2008 International Conference on Alzheimer's Disease; 2008 Jul 26-31; Chicago (IL).
48. Shua-Haim JR, Yap C, Kretov A, et al. Results of next day crossover study of galantamine ER (Razadyne Er) to rivastigmine patch (Exelon patch) in Alzheimer's disease patients: a two-month clinical experience [abstract no. P2-410]. 2008 International Conference on Alzheimer's Disease; 2008 Jul 26-31; Chicago (IL).
49. Shua-Haim J, Yap C, Kretov A, et al. Results of next day crossover study of donepezil (Aricept) to rivastigmine patch (Exelon patch) in Alzheimer's disease patients: a twomonth clinical experience [abstract no. P2-407]. 2008 International Conference on Alzheimer's Disease; 2008 Jul 26-31; Chicago (IL).
50. Shua-Haim J, Yap C, Kretov A, et al. Results of two-step crossover study of donepezil (Aricept) to rivastigmine patch (Exelon Patch) in Alzheimer's disease patients: a two-month clinical experience [abstract no. P2-409]. 2008 International Conference on Alzheimer's Disease; 2008 Jul 26-31; Chicago (IL).
51. Lee JH, Sevigny J. Effects of Body Weight on Tolerability of Rivastigmine Transdermal Patch: a Post-hoc Analysis of a Double-blind Trial in Patients With Alzheimer Disease. Alzheimer Dis Assoc Disord 2011 Jan 31; 25 (1): 58-62.
52. Cummings JL, Farlow MR, Meng X, et al. Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer's disease. Clin Drug Invest 2010; 30 (1): 41-9.
53. Sadowsky CH, Farlow MR, Meng X, et al. Safety and tolerability of rivastigmine transdermal patch compared with rivastigmine capsules in patients switched from donepezil: data from three clinical trials. Int J Clin Pract 2010; 64 (2): 188-93.
54. Safirstein B, Meng X, Olin JT. Rivastigmine and concomitant memantine in Alzheimer's disease: safety and tolerability. CNS Spectr 2010; 15 (9): 594-8.
55. Sadowsky CH, Farlow MR, Atkinson L, et al. Switching from donepezil to rivastigmine is well tolerated: results of an open-label safety and tolerability study. Prim Care Companion J Clin Psychiatry 2005; 7 (2): 43-8. (Pubitemid 41783231)
56. Figiel GS, Sadowsky CH, Strigas J, et al. Safety and efficacy of rivastigmine in patients with Alzheimer's disease not responding adequately to donepezil: an open-label study. Prim Care Companion J Clin Psych 2008; 10 (4): 291-8.
57. Olin JT, Bhatnagar V, Reyes P, et al. Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (study ENA713B US32). Int J Geriatr Psychiatry 2010 Apr; 25 (4): 419-26.
58. Exelon patch (rivastigmine transdermal preparation): Japanese prescribing information. Tokyo: Novartis Pharma K. K., 2011.
59. Rivastach (rivastigmine transdermal preparation): Japanese prescribing information. Osaka: Ono Pharmaceutical Co., 2011.
60. Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005 Dec 17; 366 (9503): 2112-7. (Pubitemid 41797645)
61. National Institute of Aging. Alzheimer's disease: a looming national crisis [online]. Available from URL: http://www. nia.nih.gov/Alzheimers/ Publications/ADProgress2005-2006/Part1/looming.htm [Accessed 2010 Sep 21].
62. Alva G, Cummings JL. Relative tolerability of Alzheimer's disease treatments. Psychiatry (Edgmont) 2008 Nov; 5 (11): 27-36.
63. Hansen RA, Gartlehner G, Webb AP, et al. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. Clin Interv Aging 2008; 3 (2): 211-25. (Pubitemid 352037861)
64. Bassil N, Grossberg GT. Novel regimens and delivery systems in the pharmacological treatment of Alzheimer's disease. CNS Drugs 2009; 23 (4): 293-307.
65. Small G, Dubois B. A review of compliance to treatment in Alzheimer's disease: potential benefits of a transdermal patch. Curr Med Res Opin 2007 Nov; 23 (11): 2705-13. (Pubitemid 350146408)
66. Peterson TA. Transdermal drug formulation and process development [online].Available from URL: http://pharmtech. findpharma.com/pharmtech/data/ articlestandard//pharm tech/232003/59304/article.pdf [Accessed 2011 Jan 14].
67. Nagy B, Brennan A, Brandtmuller A, et al. Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer's disease in the UK using MMSE- and ADLbased models. Int J Geriatr Psychiatry 2011 May; 26 (5): 483-94.
68. Farlow MR, Grossberg G, Gauthier S, et al. The ACTION study: methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe Alzheimer's disease. Curr Med Res Opin 2010 Oct; 26 (10): 2441-7.
69. Grossberg GT, Olin JT, Somogyi M, et al. Dose effects associated with rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease. Int J Clin Pract 2011 Apr; 65 (4): 465-71